IGC Pharma (IGC) Free Cash Flow (2010 - 2025)
IGC Pharma (IGC) posted quarterly Free Cash Flow of -$2.1 million for Q3 2025, down 106.73% year-over-year from $31.5 million in Q3 2024, and down 49.75% quarter-over-quarter from -$1.4 million in Q2 2025.
IGC Pharma (IGC) Free Cash Flow (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Free Cash Flow for 16 consecutive years, with -$2.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Free Cash Flow fell 106.73% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$3.5 million (up 27.98% YoY), while the FY2026 annual figure was -$1.2 million, up 75.06% from the prior year.
- Free Cash Flow fell to -$2.1 million in Q3 2025 per IGC's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$541000.0 in Q1 2024 and bottomed at -$4.0 million in Q1 2021.
- Historically, Free Cash Flow has averaged -$1.7 million across 5 years, with a median of -$1.7 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 71.6% — and 2025, when it tumbled 106.73%.
- IGC Pharma's Free Cash Flow stood at -$2.4 million in 2021, then increased by 6.85% to -$2.2 million in 2022, then increased by 25.78% to -$1.7 million in 2023, then climbed by 18.79% to -$1.3 million in 2024, then slumped by 57.66% to -$2.1 million in 2025.
- Business Quant data shows IGC's Free Cash Flow at -$2.1 million in Q3 2025, -$1.4 million in Q2 2025, and -$748000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.12 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -1.42 Mn |
| Jun 30, 2025 | -1.42 Mn |
| Mar 31, 2025 | -748,000.00 |
| Mar 31, 2025 | -748,000.00 |
| Dec 31, 2024 | -1.34 Mn |
| Dec 31, 2024 | -1.34 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | -541,000.00 |
| Mar 31, 2024 | -541,000.00 |
| Dec 31, 2023 | -1.66 Mn |
| Dec 31, 2023 | -1.66 Mn |
| Sep 30, 2023 | -1.65 Mn |
| Sep 30, 2023 | -1.65 Mn |
| Jun 30, 2023 | -1.49 Mn |
| Jun 30, 2023 | -1.49 Mn |